

**ERV3 Antibody (C-Term) Blocking peptide**  
**Synthetic peptide**  
**Catalog # BP13435b****Specification**

---

**ERV3 Antibody (C-Term) Blocking peptide - Product Information**Primary Accession [Q14264](#)**ERV3 Antibody (C-Term) Blocking peptide - Additional Information****Gene ID** 2086**Other Names**

Endogenous retrovirus group 3 member 1 Env polyprotein, ERV-3 envelope protein, ERV3 envelope protein, ERV3-1 envelope protein, Envelope polyprotein, HERV-R envelope protein, ERV-R envelope protein, HERV-R\_7q212 provirus ancestral Env polyprotein, Surface protein, SU, Transmembrane protein, TM, ERV3-1, ERV3

**Target/Specificity**

The synthetic peptide sequence used to generate the antibody AP13435b was selected from the C-term region of ERV3. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

**Format**

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

**Storage**

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

**Precautions**

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

**ERV3 Antibody (C-Term) Blocking peptide - Protein Information****Name** ERV3-1**Synonyms** ERV3**Function**

Retroviral envelope proteins mediate receptor recognition and membrane fusion during early infection. Endogenous envelope proteins may have kept, lost or modified their original function during evolution. This endogenous envelope protein has lost its fusogenic properties. It can inhibit cell growth through decrease expression of cyclin B1 and increased expression of p21 in vitro.

**Cellular Location**

Virion.

**Tissue Location**

Expressed at higher level in adrenal, sebaceous glands and placenta. Expressed at lower level in bone marrow, brain, breast, colon, heart, kidney, liver, lung, ovary, PBL, prostate, skin, spleen, testis, thymus, thyroid, trachea

**ERV3 Antibody (C-Term) Blocking peptide - Protocols**

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)

**ERV3 Antibody (C-Term) Blocking peptide - Images****ERV3 Antibody (C-Term) Blocking peptide - Background**

The human genome includes many retroelements including the human endogenous retroviruses (HERVs). ERV3, one of the most studied HERVs, is thought to have integrated 30 to 40 million years ago and is present in higher primates with the exception of gorillas. Taken together, the observation of genome conservation, the detection of transcript expression, and the presence of conserved ORFs is circumstantial evidence for a functional role. A functional role is also suggested by the observation that downregulation of ERV3 is reported in choriocarcinoma. [provided by RefSeq].

**ERV3 Antibody (C-Term) Blocking peptide - References**

Andersson, A.C., et al. J. Virol. 79(14):9270-9284(2005) Herve, C.A., et al. Genomics 83(5):940-943(2004) Blaise, S., et al. Proc. Natl. Acad. Sci. U.S.A. 100(22):13013-13018(2003) de Parseval, N., et al. J. Virol. 77(19):10414-10422(2003) Andersson, A.C., et al. Virology 297(2):220-225(2002)